Back to Search
Start Over
Combining old and new concepts in targeting telomerase for cancer therapy: transient, immediate, complete and combinatory attack (TICCA).
- Source :
-
Cancer Cell International . 9/7/2023, Vol. 23 Issue 1, p1-24. 24p. - Publication Year :
- 2023
-
Abstract
- Telomerase can overcome replicative senescence by elongation of telomeres but is also a specific element in most cancer cells. It is expressed more vastly than any other tumor marker. Telomerase as a tumor target inducing replicative immortality can be overcome by only one other mechanism: alternative lengthening of telomeres (ALT). This limits the probability to develop resistance to treatments. Moreover, telomerase inhibition offers some degree of specificity with a low risk of toxicity in normal cells. Nevertheless, only one telomerase antagonist reached late preclinical studies. The underlying causes, the pitfalls of telomerase-based therapies, and future chances based on recent technical advancements are summarized in this review. Based on new findings and approaches, we propose a concept how long-term survival in telomerase-based cancer therapies can be significantly improved: the TICCA (Transient Immediate Complete and Combinatory Attack) strategy. [ABSTRACT FROM AUTHOR]
- Subjects :
- *TELOMERASE
*CANCER treatment
*TUMOR markers
*TELOMERES
*CANCER cells
Subjects
Details
- Language :
- English
- ISSN :
- 14752867
- Volume :
- 23
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Cancer Cell International
- Publication Type :
- Academic Journal
- Accession number :
- 171806172
- Full Text :
- https://doi.org/10.1186/s12935-023-03041-2